In part 3 of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the personalization of medicine as the future of diabetes care.
Read More »Lisa Latts Part 4, Watson History and Additional Watson Research
In part 4 of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the genesis of Watson and the work currently in the pipeline.
Read More »Lisa Latts Part 5, Watson Cardiovascular Analysis
In part 5 of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the findings from the cardiovascular study for use in Watson.
Read More »Lisa Latts Part 6, Why Did You Move From A Traditional Medical Practice
In part 6 of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about her desire to make the healthcare system work more effectively and improve the practice of medicine.
Read More »Lisa Latts Part 7, Accessing Watson Information
In part 7, the conclusion of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the Watson tools available and how to access them.
Read More »Glycemic Variability and Development of Retinopathy
Study assesses glycemic variability via continuous glucose monitoring and compares it against incidence of diabetic retinopathy to determine if correlation exists.
Read More »Association of Severe Hypoglycemia and Cardiovascular Outcomes in Type 2 Diabetes
Trial assesses if link exists between severe hypoglycemia and adverse cardiovascular outcomes in veterans.
Read More »Can Automated Text Messages Improve HbA1c?
Personalized messages based on motivational interviewing principles compared to usual care to determine if any significant difference in self-management of type 2 diabetes.
Read More »CGM for the Less-Intensive Patient Population
Guest Post by David Kliff, Editor, Diabetic Investor
Although we haven’t gotten there just yet, it’s no longer a question of if type 2’s start using CGM, but when they do and how they use it. CGM is not like an insulin pump when it comes to having a finite market size. CGM is a valuable tool regardless of whether the patient uses insulin.
Appropriateness of Time in Range as a Measure of Diabetes Outcomes
Time in glycemic range inversely correlated to risk of developing vascular complications in patients with diabetes
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.